Big Data, personalized medicines, and parenteral manufacturing are just a few of the topics to be discussed at the 2nd PDA Europe Annual Meeting: Global Healthcare of the Present
& the Future, June 13–14, in Berlin. But no meeting in this area would be complete without discussions of the continually changing regulatory environment that poses a variety of challenges for the pharmaceutical industry. The
conference will include a discussion of inspection trends from the regulator and industry perspectives.
Leading global regulators will be on hand to offer their perspectives. PDA has confirmed the following regulatory officials for the opening plenary session: Paul Hargreaves, Chair, PIC/S, Emer Cooke, WHO, (via remote), Terence Madigan, MHRA, Rainer Gnibl, District Government of Upper Bavaria, and Rassoul Dinarvand, Head, Iran FDA. Hargreaves will speak on GMP harmonization, and Dinarvand will participate on a panel discussion of international pharmaceutical regulations.
Dinarvand has also been invited to speak in a preconference workshop, Business Opportunities in Iran, on June 12. At another June 12 preconference workshop, Andrew Hopkins of the MHRA and German GMP inspector Beate Reutter will speak about revisions to Annex 1.
Learn more about other speakers and sessions at this meeting.